Intellipharmaceutics delays filing annual financial statements on Feb 28, 2024, due to ongoing audit.
Intellipharmaceutics, a Canadian pharmaceutical company specializing in controlled-release and targeted-release oral solid dosage drugs, announced on Feb 26, 2024, that it will be delayed in filing its annual audited financial statements and annual information form due on Feb 28, 2024. The company is working diligently to complete the audit and aims to file the required documents as soon as possible.
February 27, 2024
6 Articles